Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Vir Biotechnology (Switzerland) · University of Washington · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,138
total citations
- FWCI
- 45.43
- Percentile
- 100%
- References
- 95
Citations per year
Authors
25- DPDora PintoCorresponding
Vir Biotechnology (Switzerland)
- YPYoung‐Jun Park
University of Washington
- MBMartina Beltramello
Vir Biotechnology (Switzerland)
- ACAlexandra C. Walls
University of Washington
- MAM. Alejandra Tortorici
Centre National de la Recherche Scientifique, Institut Pasteur, University of Washington
Topics & keywords
Topics
Keywords
- Virology
- Monoclonal antibody
- Antibody
- Neutralization
- Epitope
- Coronavirus
- Glycoprotein
- Biology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- UDU.S. Department of EnergyAwards: -AC02-05CH11231, Contract No. DE-AC02-05CH11231, 05CH11231, No. DE-AC02-05CH11231, AC02-05CH11231, DE-AC02, DE-AC02-05CH11231, DE-AC02-
- BWBurroughs Wellcome FundAward: DE-AC02-05CH11231
- UOUniversity of Washington
- OOOffice of ScienceAwards: AC02-05CH11231, -AC02-05CH11231, DE-AC02, No. DE-AC02-05CH11231, Contract No. DE-AC02-05CH11231
- NINational Institute of General Medical SciencesAwards: DE-AC02-05CH11231, R01GM120553
- NINational Institute of Allergy and Infectious DiseasesAwards: HHSN272201700059C, 75N93019C00062